### South Africa

#### Tuberculosis profile

**Population 2018**
58 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate per 100,000 population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>301 (215–400)</td>
<td>520 (373–691)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>177 (127–235)</td>
<td>306 (219–406)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence²</td>
<td>11 (7.2–16)</td>
<td>19 (12–28)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>21 (20–23)</td>
<td>37 (35–39)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>42 (30–57)</td>
<td>73 (51–99)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- New cases: 3.4% (2.5–4.3)
- Previously treated cases: 7.1% (4.8–9.5)

**TB case notifications, 2018**

- Total new and relapse: 227,999
  - % tested with rapid diagnostics at time of diagnosis: 71%
  - % with known HIV status: 90%
  - % pulmonary: 89%
  - % bacteriologically confirmed³⁰⁰: 70%
  - % children aged 0-14 years: 7%
  - % women: 37%
  - % men: 56%

**Total cases notified**: 235,652

---

#### Universal health coverage and social protection

**TB treatment coverage (notified/estimated incidence), 2018**: 76% (57–110)

**TB patients facing catastrophic total costs**: 22% (14–30)

**TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 22% (14–30)

**Patients with known HIV status who are HIV-positive**: 120,862 (59%)
- on antiretroviral therapy: 104,625 (87%)

---

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance ³⁰⁰: 92%
  - New cases: 92%
  - Previously treated cases: 94%

**Laboratory-confirmed cases**

**Patients started on treatment**:
- MDR/RR-TB: 13,199, XDR-TB: 553
- MDR/RR-TB: 9,558, XDR-TB: 539

**MDR/RR-TB cases tested for resistance to second-line drugs**: 7,469

---

#### Treatment success rate and cohort size

**New and relapse cases registered in 2017**: 77% 240,332

**Previously treated cases, excluding relapse, registered in 2017**: 59% 6,508

**HIV-positive TB cases registered in 2017**: 75% 134,672

**MDR/RR-TB cases started on second-line treatment in 2016**: 54% 11,159

**XDR-TB cases started on second-line treatment in 2016**: 58% 601

---

#### TB preventiv e treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 65%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 59% (54–65)

---

#### TB financing, 2019

**National TB budget (US$ millions)**: 240

**Funding source**: 87% domestic, 13% international, 0% unfunded

---

* Ranges represent uncertainty intervals
² MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
³⁰⁰ Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

**Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.**

Generated: 2020-03-28  
Data: www.who.int/tb/data